287 related articles for article (PubMed ID: 31193737)
1. Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth.
Wu Z; Ichinose T; Naoe Y; Matsumura S; Villalobos IB; Eissa IR; Yamada S; Miyajima N; Morimoto D; Mukoyama N; Nishikawa Y; Koide Y; Kodera Y; Tanaka M; Kasuya H
Mol Ther Oncolytics; 2019 Jun; 13():107-115. PubMed ID: 31193737
[TBL] [Abstract][Full Text] [Related]
2. Antitumor Efficacy of Oncolytic Herpes Virus Type 1 Armed with GM-CSF in Murine Uveal Melanoma Xenografts.
Liu S; Liu F; Zhao M; Zhang J
Cancer Manag Res; 2020; 12():11803-11812. PubMed ID: 33239914
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic Virus Therapy with HSV-1 for Hematological Malignancies.
Ishino R; Kawase Y; Kitawaki T; Sugimoto N; Oku M; Uchida S; Imataki O; Matsuoka A; Taoka T; Kawakami K; van Kuppevelt TH; Todo T; Takaori-Kondo A; Kadowaki N
Mol Ther; 2021 Feb; 29(2):762-774. PubMed ID: 33038943
[TBL] [Abstract][Full Text] [Related]
4. Developing oncolytic
Ebrahimi S; Makvandi M; Abbasi S; Azadmanesh K; Teimoori A
Iran J Basic Med Sci; 2020 Jul; 23(7):937-944. PubMed ID: 32774817
[TBL] [Abstract][Full Text] [Related]
5. Identification of in vitro and in vivo oncolytic effect in colorectal cancer cells by Orf virus strain NA1/11.
Chen D; Wang R; Long M; Li W; Xiao B; Deng H; Weng K; Gong D; Liu F; Luo S; Hao W
Oncol Rep; 2021 Feb; 45(2):535-546. PubMed ID: 33416161
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic effects of the recombinant Newcastle disease virus, rAF-IL12, against colon cancer cells in vitro and in tumor-challenged NCr-Foxn1nu nude mice.
Syed Najmuddin SUF; Amin ZM; Tan SW; Yeap SK; Kalyanasundram J; Veerakumarasivam A; Chan SC; Chia SL; Yusoff K; Alitheen NB
PeerJ; 2020; 8():e9761. PubMed ID: 33354412
[TBL] [Abstract][Full Text] [Related]
7. Anti-viral immunity in the tumor microenvironment: implications for the rational design of herpes simplex virus type 1 oncolytic virotherapy.
Rider PJF; Uche IK; Sweeny L; Kousoulas KG
Curr Clin Microbiol Rep; 2019 Dec; 6(4):193-199. PubMed ID: 33344108
[TBL] [Abstract][Full Text] [Related]
8. Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of
Froechlich G; Caiazza C; Gentile C; D'Alise AM; De Lucia M; Langone F; Leoni G; Cotugno G; Scisciola V; Nicosia A; Scarselli E; Mallardo M; Sasso E; Zambrano N
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33213060
[TBL] [Abstract][Full Text] [Related]
9. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Herpes Simplex Virus Type 2 Can Effectively Inhibit Colorectal Cancer Liver Metastasis by Modulating the Immune Status in the Tumor Microenvironment and Inducing Specific Antitumor Immunity.
Zhang W; Zeng B; Hu X; Zou L; Liang J; Song Y; Liu B; Liu S
Hum Gene Ther; 2021 Feb; 32(3-4):203-215. PubMed ID: 33176492
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1.
Kim KJ; Moon D; Kong SJ; Lee YS; Yoo Y; Kim S; Kim C; Chon HJ; Kim JH; Choi KJ
Gene Ther; 2021 Apr; 28(3-4):186-198. PubMed ID: 33149278
[TBL] [Abstract][Full Text] [Related]
12. Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors.
Oh CM; Chon HJ; Kim C
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086754
[TBL] [Abstract][Full Text] [Related]
13. Macrophage polarization contributes to the efficacy of an oncolytic HSV-1 targeting human uveal melanoma in a murine xenograft model.
Liu S; Zhang J; Fang S; Zhang Q; Zhu G; Tian Y; Zhao M; Liu F
Exp Eye Res; 2021 Jan; 202():108285. PubMed ID: 33039456
[TBL] [Abstract][Full Text] [Related]
14. Arming HSV-Based Oncolytic Viruses with the Ability to Redirect the Host's Innate Antiviral Immunity to Attack Tumor Cells.
Fu X; Tao L; Wu W; Zhang X
Mol Ther Oncolytics; 2020 Dec; 19():33-46. PubMed ID: 33024817
[TBL] [Abstract][Full Text] [Related]
15. Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability.
Kennedy EM; Farkaly T; Grzesik P; Lee J; Denslow A; Hewett J; Bryant J; Behara P; Goshert C; Wambua D; De Almeida A; Jacques J; Deavall D; Rottman JB; Glorioso JC; Finer MH; Haines BB; Quéva C; Lerner L
Mol Ther Oncolytics; 2020 Sep; 18():476-490. PubMed ID: 32953982
[TBL] [Abstract][Full Text] [Related]
16. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
[TBL] [Abstract][Full Text] [Related]
17. TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling.
Heiniö C; Havunen R; Santos J; de Lint K; Cervera-Carrascon V; Kanerva A; Hemminki A
Cells; 2020 Mar; 9(4):. PubMed ID: 32225009
[TBL] [Abstract][Full Text] [Related]
18. Folate-conjugated herpes simplex virus for retargeting to tumor cells.
Ye ZQ; Zou CL; Chen HB; Lv QY; Wu RQ; Gu DN
J Gene Med; 2020 Jul; 22(7):e3177. PubMed ID: 32096291
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a third-generation oncolytic herpes simplex virus in neuroendocrine tumor xenograft models.
Matsushima H; Kaibori M; Hatta M; Ishizaki M; Nakatake R; Okumura T; Yoshii K; Todo T
Oncotarget; 2019 Dec; 10(67):7132-7141. PubMed ID: 31903171
[TBL] [Abstract][Full Text] [Related]
20. Engineering HSV-1 Vectors for Gene Therapy.
Goins WF; Huang S; Hall B; Marzulli M; Cohen JB; Glorioso JC
Methods Mol Biol; 2020; 2060():73-90. PubMed ID: 31617173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
